Medplus Health Services: Should You Buy, Hold, or Sell Right Now?
- September 3, 2026
- Posted by: Kunal Singla
- Category: Market
Medplus Health Services share price Rs 659.95 (NSE), near its 52-week low. 52-week range Rs 648 to Rs 1,022.20. Q1 FY27 revenue up 21.9% YoY, profit down 21.7%.
Quick Answer
Medplus Health Services share price is trading around Rs 660, close to its 52-week low of Rs 648 and well off its 52-week high of Rs 1,022.20. Q1 FY27 revenue grew a strong 21.9 percent year on year to Rs 1,899.43 crore, but net profit fell 21.7 percent to Rs 33.17 crore, likely reflecting the costs of continued store network expansion for India’s second-largest pharmacy retail chain. The stock trades at 37.7 times earnings, a discount to the pharmacy retail sector average near 69 times. Investors focused on the strong revenue growth from store expansion may see the pullback near the 52-week low as an opportunity, while others may want profitability to improve before adding exposure.
Medplus Health Services share price is trading close to its 52-week low of Rs 648, with Medplus share price near Rs 660 on the NSE, well off its 52-week high of Rs 1,022.20. With strong revenue growth but declining profit in Q1 FY27, investors are asking whether this pharmacy retail chain is a stock to buy near its lows, a hold, or a sell given the margin pressure.
This Medplus stock analysis walks through the Q1 FY27 numbers, valuation against the pharmacy retail sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Medplus Health Services
Keep this backdrop in mind when reading the rest of this Medplus Health Services share price review. Before deciding on Medplus Health Services share price, it helps to understand the underlying business. Medplus Health Services Ltd. operates India’s second-largest pharmacy retail chain, selling prescription and over-the-counter medicines, wellness products and other healthcare items through a large network of retail stores across India. The company has been aggressively expanding its store network to capture growing demand for organised pharmacy retail.
As a pharmacy retail chain in expansion mode, Medplus typically incurs upfront costs for new store openings, including rent, staffing and initial inventory, before these stores reach mature profitability, which can weigh on consolidated margins during periods of rapid network growth.
Medplus Health Services Share Price Today: Key Levels
This snapshot is the starting point for any Medplus Health Services share price discussion. The table below summarises where Medplus share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Medplus CMP (NSE) | Rs 659.95 |
| Medplus CMP (BSE) | Rs 660.40 |
| 52-Week High | Rs 1,022.20 |
| 52-Week Low | Rs 648.00 |
| Market Capitalisation | Approximately Rs 7,934 crore |
| NSE Volume (latest session) | 524 shares |
Medplus share price is trading near its 52-week low, even as the company continues to post strong revenue growth from store network expansion, reflecting the market’s focus on the accompanying profit decline.
Check the Univest Screener for Live Stock Data
Medplus Health Services Financial Performance
These figures anchor the rest of this Medplus Health Services share price review. Track this line item closely if you are following Medplus Health Services share price closely. The Medplus Health Services share price trend is closely tied to how these numbers evolve each quarter. Medplus reported Q1 FY27 (June 2026 quarter) revenue of Rs 1,899.43 crore, up 21.9 percent year on year from Rs 1,557.65 crore, while net profit fell 21.7 percent year on year to Rs 33.17 crore from Rs 42.34 crore, indicating that store expansion costs and other pressures offset much of the benefit from the strong topline growth.
For the full year FY26, the company reported revenue of Rs 6,963.79 crore, up 12.6 percent year on year, with net profit of Rs 219.61 crore, up 46.2 percent from Rs 150.23 crore in FY25, showing that the full year as a whole was actually a period of strong profit growth before the most recent quarter’s decline, worth keeping in mind when assessing the latest results.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 1,899.43 crore | Rs 33.17 crore | +21.9% revenue, -21.7% profit YoY |
| FY26 (full year) | Rs 6,963.79 crore | Rs 219.61 crore | +12.6% revenue, +46.2% profit YoY |
Valuation Check: Is Medplus Health Services Share Price Expensive?
This context matters for anyone assessing Medplus Health Services share price today. It is one of the clearest signals available on Medplus Health Services share price today. Any view on Medplus Health Services share price should start from these valuation multiples. Medplus share price currently reflects a price to earnings ratio of about 37.7 times trailing earnings, a discount to the pharmacy retail sector average of roughly 68.8 times. The price to book ratio stands near 4 times, with return on equity at 11.12 percent.
Debt to equity of 0.72 is moderate for a retail chain funding store network expansion. Historically, pharmacy retail chains investing in new store growth have seen near-term margin pressure that eases as stores mature, so the current discount to sector, alongside strong full-year FY26 profit growth, suggests the market may be reacting more to the near-term quarter than to the company’s overall trajectory.
Technical Signals: What the Chart Shows
Watching Medplus Health Services share price over consecutive sessions gives a clearer read than any single print. Price action here often foreshadows the next move in Medplus Health Services share price. Medplus share price is currently positioned about 36 percent below its 52-week high of Rs 1,022.20 and just above its 52-week low of Rs 648, placing it near the bottom of its annual trading range following the profit-pressured Q1 FY27 results. A stock trading this close to its low after a quarter of profit decline, despite strong revenue growth, often reflects the market’s near-term caution around new store profitability timelines.
Trading volumes remain moderate, so investors should track Medplus share price over the next couple of quarters to see whether profitability recovers as recently opened stores mature, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Medplus’ live price and technical levels.
Shareholding Pattern
This detail is a useful reference point for Medplus Health Services share price discussions. Shifts here can influence Medplus Health Services share price more than headline news on some sessions. Medplus Health Services is a promoter-founded pharmacy retail chain that has scaled to become India’s second-largest organised pharmacy retailer. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Medplus Health Services
- Strong revenue growth from store expansion: Q1 FY27 revenue grew 21.9 percent year on year, reflecting the scale benefits of Medplus’ continued pharmacy store network growth.
- Strong full-year FY26 profit growth: Full-year FY26 profit grew 46.2 percent year on year, showing the business delivered strong profitability over a longer period before the latest quarter’s dip.
- Market leadership in organised pharmacy retail: As India’s second-largest pharmacy retail chain, Medplus benefits from scale advantages in procurement and brand recognition.
- Valuation discount to sector: A 37.7x PE against a 68.8x sector average offers meaningful valuation cushion given the company’s overall growth trajectory.
Risks and Factors to Watch
- Margin pressure from store expansion costs: Q1 FY27 profit fell 21.7 percent despite strong revenue growth, likely reflecting upfront costs for new stores that have not yet reached mature profitability.
- Execution risk on continued store rollout: Sustaining growth requires continued successful new store openings and their eventual ramp-up to profitability, both of which carry execution risk.
- Competitive pharmacy retail market: Medplus operates in a competitive organised pharmacy retail market against other large chains and online pharmacy platforms.
- Working capital intensity of retail expansion: Rapid store network growth requires ongoing working capital investment in inventory and store infrastructure.
Medplus Health Services Share Price Target: What the Data Suggests
Until then, Medplus Health Services share price remains best tracked through live, verified data rather than a single fixed number. Medplus does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering strong revenue growth from store expansion, with a temporary profit dip in the latest quarter following a strong full FY26, trading at a discount to the pharmacy retail sector.
Historically, pharmacy retail chains have seen margins recover as new stores mature past their initial ramp-up period. Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Medplus Health Services: Should You Buy, Hold, or Sell Right Now?
There is no shortcut here: Medplus Health Services share price needs to be judged against your own plan. This is the core question behind Medplus Health Services share price right now. The Medplus buy or sell decision depends on whether you believe the Q1 FY27 profit dip is a temporary consequence of store expansion.
The case for buying: Value-focused investors who see the strong revenue growth and discount to sector PE as attractive, and who believe new store profitability will improve as they mature, may find the price near its 52-week low an entry point worth considering.
The case for holding: Existing shareholders who already track Medplus’ store expansion and full-year profitability trend may prefer to stay invested through this near-term dip.
The case for trimming or waiting: Investors wanting to see profitability recover before committing fresh capital, given the sharp Q1 FY27 profit decline, may prefer to wait for clearer confirmation.
Historically, expanding pharmacy retail chains have rewarded patient investors once new stores mature, so weigh this against your own investment horizon and consult a SEBI-registered investment adviser if unsure.
Conclusion
In short, Medplus Health Services share price calls for weighing these points together rather than in isolation. Medplus Health Services share price reflects India’s second-largest pharmacy retail chain delivering strong revenue growth from store expansion, even as Q1 FY27 profit declined likely due to new store costs, following a strong full FY26. Whether that makes the stock a buy, a hold or a sell right now depends on your confidence that profitability will recover as new stores mature. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Medplus a good stock to buy right now?
Ans. Medplus grew Q1 FY27 revenue 21.9 percent year on year from store network expansion, though profit fell 21.7 percent likely due to new store costs, following a strong FY26 in which profit grew 46.2 percent. The stock trades at a discount to the pharmacy retail sector, which may appeal to value-focused investors.
Q2. Why did Medplus profit fall despite strong revenue growth?
Ans. Medplus’ Q1 FY27 net profit fell 21.7 percent year on year to Rs 33.17 crore despite 21.9 percent revenue growth, likely reflecting upfront costs including rent, staffing and inventory for newly opened pharmacy stores that have not yet reached mature profitability.
Q3. What is the Medplus share price today?
Ans. Medplus Health Services share price is trading around Rs 660 on the NSE, near its 52-week low of Rs 648. The stock’s 52-week high is Rs 1,022.20.
Q4. What is the Medplus share price target?
Ans. Medplus does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q5. What is Medplus’ market capitalisation and PE ratio?
Ans. Medplus has a market capitalisation of approximately Rs 7,934 crore and trades at a price to earnings ratio of about 37.7 times, a discount to the pharmacy retail sector average PE of roughly 68.8 times.
Q6. Is Medplus India’s largest pharmacy chain?
Ans. Medplus Health Services is India’s second-largest organised pharmacy retail chain, operating a large network of stores selling prescription and over-the-counter medicines, wellness products and other healthcare items.
